Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Equillium Inc (NQ: EQ ) 1.139 +0.009 (+0.81%) Streaming Delayed Price Updated: 9:30 AM EDT, Oct 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Equillium Inc < Previous 1 2 3 4 5 6 Next > Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR February 17, 2023 From Equillium, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Intraday Session February 09, 2023 Via Benzinga Alphabet To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Wednesday February 08, 2023 Loop Capital boosted the price target for Alphabet Inc. (NASDAQ: GOOGL) from $120 to $125. Loop Capital analyst Rob Sanderson maintained a Buy rating. Alphabet shares fell 3.7% to $103.70 in pre-market... Via Benzinga Equillium to Present at the SVB Securities Annual Global Healthcare Conference February 07, 2023 From Equillium, Inc. Via Business Wire Autoimmune Biotech Scores $26M Payment, Up To $139M To Advance Phase 3 Research December 06, 2022 Via Benzinga Equillium Shares Ride Higher After Positive Data From Lead Asset In Kidney Inflammation September 27, 2022 Via Benzinga Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR January 13, 2023 From Equillium, Inc. Via Business Wire Metacrine, Equillium And 3 Stocks To Watch Heading Into Tuesday December 27, 2022 With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Via Benzinga Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement December 23, 2022 From Equillium, Inc. Via Business Wire Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis December 16, 2022 From Equillium, Inc. Via Business Wire Why iBio Shares Are Trading Lower By Around 48%; Here Are 23 Stocks Moving Premarket December 07, 2022 Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 71.3% to $0.7190 in pre-market trading after the company reported withdrawal of registration statement. Via Benzinga Equillium and Ono Pharmaceutical Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab December 06, 2022 From Equillium, Inc. Via Business Wire How Equillium Inc Could Help Lead The Fight Against Autoimmune Diseases December 02, 2022 Equillium Inc. (NASDAQ: EQ) is a clinical-stage biotechnology company that focuses on immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders. Via Benzinga Stocks That Hit 52-Week Lows On Friday December 02, 2022 On Friday, 72 companies hit new 52-week lows. Via Benzinga Equillium Reports Third Quarter 2022 Financial Results and Provides Corporate and Clinical Updates November 14, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker of Disease Severity in Lupus Nephritis at ACR Convergence 2022 November 14, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Initiation of Phase 2 study of EQ101 A First-in-Class Multi-Cytokine Inhibitor of IL-2, IL-9 and IL-15 Targeting Alopecia Areata November 10, 2022 From Equillium, Inc. Via Business Wire Equillium to Present at Two Upcoming Investor Conferences November 08, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit November 03, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease November 02, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference October 26, 2022 From Equillium, Inc. Via Business Wire Why NLS Pharmaceutics Shares Dipped Over 23%; Here Are 67 Biggest Movers From Yesterday September 28, 2022 Gainers Via Benzinga Why Is Equillium (EQ) Stock Soaring 20% Today? September 27, 2022 Biotech firm Equillium is on the move as it released positive data for a lupus therapeutic, though EQ stock has a tough road ahead. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Intraday Session September 27, 2022 Gainers Via Benzinga This Analyst Boosts PT On PepsiCo? Plus UBS Sees $75 For Micron Technology September 27, 2022 Deutsche Bank raised the price target on PepsiCo, Inc. (NASDAQ: PEP) from $179 to $181. Deutsche Bank analyst Steve Powers maintained a Hold rating on the stock. PepsiCo shares fell 1.2% to $166.47 on... Via Benzinga Why Bellerophon Therapeutics Shares Are Trading Higher By 24%, Here Are 44 Stocks Moving In Tuesday's Mid-Day Session September 27, 2022 Gainers Via Benzinga Here's Why Equillium Stock Is Skyrocketing September 27, 2022 Equillium Inc (NASDAQ: EQ) shares are trading higher by 23.32% to $2.38 Tuesday morning after the company reported interim results from the Type B portion of the EQUALISE study evaluating itolizumab.... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session September 27, 2022 Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. Via Benzinga Equillium Announces Positive Interim Results from the EQUALISE Study in Subjects with Lupus Nephritis September 27, 2022 From Equillium, Inc. Via Business Wire Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022 September 15, 2022 From Equillium, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.